Aim: To evaluate the efficacy of a propolis-based syrup, FARINGEL®, in preventing radiation-induced esophagitis in locally advanced lung cancer patients. Methods. Patients were treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT). Every patient received FARINGEL at the beginning of CRT until the first follow-up. The data of the study group were compared with the data of a control group treated without the administration of the syrup. Results: Forty-five patients were enrolled. Forty-one (91.1%) completed the protocol and were evaluable for esophagitis. Grade ≥2 toxicity occurred in 9/41 patients (22%). No differences in overall toxicity were detected between the study group and the control group (n = 55, 60.9 vs. 54.5%; p = ns). Grade 2–3 esophagitis was lower in the study group in comparison with the control group (22 and 38%, respectively), but statistical significance was not reached (p = 0.09). However, the onset of grade ≥2 esophagitis was delayed in the study group compared to the control group, occurring at higher doses of RT (41.8 vs. 25.4 Gy; p < 0.001). Furthermore, the mean number of interruption days for esophagitis was lower in the study group than in the control group (0.6 ± 2.0 vs. 2.1 ± 3.6; p = 0.025). Conclusion: FARINGEL was well-tolerated and delayed esophagitis that was induced by CRT for locally advanced lung cancer.

1.
Rose J, Rodrigues G, Yaremko B, Lock M, D’Souza D: Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 2009; 91: 282–287.
2.
Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB: Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010; 76:S86–S93.
3.
Robertson JM, Ten Haken RK, Hazuka MB, et al: Dose escalation for non-small-cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1079–1085.
4.
Ahn SJ, Kahn D, Zhou S, Yu X, et al: Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 2005; 61: 335–347.
5.
Sonis ST, Elting LS, Keefe DM, et al: Mucositis study section of the Multinational Association for Supportive Care in Cancer: International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995–2025.
6.
Zimmermann FB, Geinitz H, Feldmann HJ: Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. Strahlenther Onkol 1998; 174(suppl III): 78–81.
7.
Chapet O, Fraas BA, Ten Haken RK: Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors. Int J Radiat Oncol Biol Phys 2006; 65: 255–265.
8.
Meredith R, Salter M, Kim R, et al: Sucralfate for radiation mucositis: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 37: 275–279.
9.
Sur R, Kochhar R, Singh D: Oral sucralfate in acute radiation esophagitis. Acta Oncol 1994; 33: 61–63.
10.
McGinnis W, Loprinzi C, Buskirk S, et al: Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 1997; 15: 1239–1243.
11.
Nicolopoulos N, Mantidis A, Stathopoulos E, et al: Prophylactic administration of indomethacin for irradiation esophagitis. Radiother Oncol 1985; 3: 23–25.
12.
Soffer E, Mitros F, Doornbos F, Friedland J, Launspach J, Summers RW: Morphology and pathology of radiation-induced esophagitis. Dig Dis Sci 1994; 39: 655–660.
13.
Bradley J, Movsas B: Radiation esophagitis: predictive factors and preventive strategies. Semin Radiat Oncol 2004; 14: 280–286.
14.
Fleischer G, Dörr W: Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine. Strahlenther Onkol 2006; 182: 567–575.
15.
Savarino E, de Bortoli N, Zentilin P, et al: Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World J Gastroenterol 2012; 18: 4371–4378.
16.
Eamlamnam K, Patumraj S, Visedopas N, Thong-Ngam D: Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats. World J Gastroenterol 2006; 12: 2034–2039.
17.
Magro-Filho O, de Carvalho AC: Topical effect of propolis in the repair of sulcoplasties by the modified Kazanjian technique. Cytological and clinical evaluation. J Nihon Univ Sch Dent 1994; 36: 102–111.
18.
Parente LM, Lino Júnior Rde S, Tresvenzol LM, Vinaud MC, de Paula JR, Paulo NM: (2012) Wound-healing and anti-inflammatory effect in animal models of Calendula officinalis L. growing in Brazil. Evid Based Complement Alternat Med 2012; 2012: 375671.
19.
Ramella S, Trodella L, Mineo TC, et al: Beams arrangement in non-small cell lung cancer (NSCLC) according to PTV and dosimetric parameters predictive of pneumonitis. Med Dosim 2010; 35: 169–178.
20.
Byhardt RW, Scott C, Sause WT, et al: Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998; 42: 469–478.
21.
Singh AK, Lockett MA, Bradley JD: Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2003; 55: 337–341.
22.
Hirota S, Tsujino K, Endo M, et al: Dosimetric predictors of radiation esophagitis in patients treated for non-small cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 291–295.
23.
Choy H, Akerley W, Safran H, et al: Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 1998; 16: 3316–3322.
24.
Wei X, Liu HH, Tucker SL, et al: Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 100–107.
25.
Palma DA, Senan S, Oberije C, et al: Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 87: 690–696.
26.
Antonadou D, Coliarakis N, Synodinou M, et al: Randomized phase III trial of radiation treatment plus/minus amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 915–922.
27.
Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer. J Clin Oncol 2003; 21: 1767–1774.
28.
Komaki R, Lee JS, Milas L, et al: Effect of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004; 58: 1369–1377.
29.
Vidal-Casariego A, Calleja-Fernández A, Ballesteros-Pomar MD, Cano-Rodríguez I: Efficacy of glutamine in the prevention of oral mucositis and acute radiation-induced esophagitis: a retrospective study. Nutr Cancer 2013; 65: 424–429.
30.
Algara M, Rodríguez N, Vinals P, et al: Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007; 69: 342–349.
31.
Hallqvist A, Bergman B, Nyman J: Health-related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab – pooled results from two prospective clinical trials. Radiother Oncol 2012; 104: 39–44.
32.
Pijls-Johannesma M, Houben R, Boersma L, et al: High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol 2009; 91: 443–448.
33.
Auchter RM, Scholtens D, Adak S, Wagner H, Cella DF, Mehta MP: Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 2001; 50: 1199–1206.
34.
Langendijk JA, Aaronson NK, de Jong JM, et al: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001; 19: 2123–2133.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.